Hyperforin in St. John’s wort drug interactions (original) (raw)

• Behnke K, Jensen GS, Graubaum HJ, Gruenwald J (2002) Hypericum perforatum versus fluoxetine in the treatment of mild to moderate depression. Adv Ther 19(1):43–52
  PubMed Google Scholar
• Bjerkenstedt L, Edman GV, Alken RG, Mannel M (2005) Hypericum extract LI 160 and fluoxetine in mild to moderate depression: a randomized, placebo-controlled multi-center study in outpatients. Eur Arch Psychiatry Clin Neurosci 255(1):40–47
  Article PubMed Google Scholar
• Schrader E (2000) Equivalence of St John’s wort extract (Ze 117) and fluoxetine: a randomized, controlled study in mild-moderate depression. Int Clin Psychopharmacol 15(2):61–68
  PubMed CAS Google Scholar
• Brenner R, Azbel V, Madhusoodanan S, Pawlowska M (2000) Comparison of an extract of hypericum (LI 160) and sertraline in the treatment of depression: a double-blind, randomized pilot study. Clin Ther 22(4):411–419
  Article PubMed CAS Google Scholar
• Gastpar M, Singer A, Zeller K (2005) Efficacy and tolerability of hypericum extract STW3 in long-term treatment with a once-daily dosage in comparison with sertraline. Pharmacopsychiatry 38(2):78–86
  Article PubMed CAS Google Scholar
• Philipp M, Kohnen R, Hiller KO (1999) Hypericum extract versus imipramine or placebo in patients with moderate depression: randomised multicentre study of treatment for eight weeks. BMJ 319(7224):1534–1538
  PubMed CAS Google Scholar
• Woelk H (2000) Comparison of St John’s wort and imipramine for treating depression: randomised controlled trial. BMJ 321(7260):536–539
  Article PubMed CAS Google Scholar
• Schulz V (2002) Clinical trials with hypericum extracts in patients with depression–results, comparisons, conclusions for therapy with antidepressant drugs. Phytomedicine 9(5):468–474
  Article PubMed Google Scholar
• Butterweck V (2003) Mechanism of action of St John’s wort in depression: what is known? CNS Drugs 17(8):539–562
  Article PubMed CAS Google Scholar
• Melzer M, Fuhrken D, Kolkmann R (1998) Hyperforin im Johanniskraut. Dt Apoth Ztg 138(49):56–62
  Google Scholar
• Brattstroem A (2002) Der Johanniskrautextrakt ZE 117: Wirksamkeit und Sicherheit. DAZ 30:97–99
  Google Scholar
• Willmar Schwabe GC (1997) Stable extract of Hypericum perforatum L., process for preparing the same and pharmaceutical composition. International Patent, WO 97/13489
• Willmar Schwabe GC (1998) Stable extract of Hypericum perforatum L., a method for producing the same, and corresponding pharmaceutical preparations. International Patent, WO 98/44936
• Arold G, Donath F, Maurer A, Diefenbach K, Bauer S, Henneicke-von Zepelin HH, Friede M, Roots I (2005) No relevant interaction with alprazolam, caffeine, tolbutamide, and digoxin by treatment with a low-hyperforin St John’s wort extract. Planta Med 71(4):331–337
  Article PubMed CAS Google Scholar
• Mai I, Bauer S, Perloff E, Johne A, Uehleke B, Frank B, Budde K, Roots I (2004) Hyperforin content determines the magnitude of the St. John’s wort-cyclosporine drug interaction. Clin Pharmacol Ther in press
• Mannel M (2004) Drug interactions with St John’s wort: mechanisms and clinical implications. Drug Saf 27(11):773–797
  Article PubMed CAS Google Scholar
• Zhou S, Chan E, Pan SQ, Huang M, Lee EJ (2004) Pharmacokinetic interactions of drugs with St John’s wort. J Psychopharmacol 18(2):262–276
  Article PubMed CAS Google Scholar
• Landrum-Michalets E (1998) Update: clinically significant cytochrome P450 drug interactions. Pharmacotherapy 18:84–112
  PubMed Google Scholar
• Smith DA, Abel SM, Hyland R, Jones BC (1998) Human cytochrome P450’s: selectivity and measurment in vivo. Xenobiotica 28:1095–1128
  Article PubMed CAS Google Scholar
• Smith S, Stubbins MJ, Harries LW, Wolf CR (1998) Molecular genetics of human cytochrome P450 monooxygenase superfamily. Xenobiotica 28:1129–1165
  Article PubMed CAS Google Scholar
• Bienvenu T, Rey E, Pons G, d’Athis P, Olive G (1991) A simple non-invasive procedure for the investigation of cytochrome P-450 IIIA dependent enzymes in humans. Int J Clin Pharmacol Ther Toxicol 29(11):441–445
  PubMed CAS Google Scholar
• Dolara P, Lodovici M, Salvadori M, Zaccara G, Muscas GC (1987) Urinary 6-beta-OH-cortisol and paracetamol metabolites as a probe for assessing oxidation and conjugation of chemicals in humans. Pharmacol Res Commun 19(4):261–273
  Article PubMed CAS Google Scholar
• Ged C, Rouillon JM, Pichard L, Combalbert J, Bressot N, Bories P, Michel H, Beaune P, Maurel P (1989) The increase in urinary excretion of 6 beta-hydroxycortisol as a marker of human hepatic cytochrome P450IIIA induction. Br J Clin Pharmacol 28(4):373–387
  PubMed CAS Google Scholar
• Roby CA, Anderson GD, Kantor E, Dryer DA, Burstein AH (2000) St John’s Wort: effect on CYP3A4 activity. Clin Pharmacol Ther 67(5):451–457
  Article PubMed CAS Google Scholar
• Gatmaitan ZC, Arias IM (1993) Structure and function of P-glycoprotein in normal liver and small intestine. Adv Pharmacol 24:77–97
  PubMed CAS Google Scholar
• Lown KS, Mayo RR, Leichtman AB, Hsiao HL, Turgeon DK, Schmiedlin-Ren P, Brown MB, Guo W, Rossi SJ, Benet LZ, Watkins PB (1997) Role of intestinal P-glycoprotein(mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther 62:248–260
  Article PubMed CAS Google Scholar
• Durr D, Stieger B, Kullak-Ublick GA, Rentsch KM, Steinert HC, Meier PJ, Fattinger K (2000) St John’s Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther 68(6):598–604
  Article PubMed CAS Google Scholar
• Wang Z, Gorski JC, Hamman MA, Huang SM, Lesko LJ, Hall SD (2001) The effects of St John’s wort (Hypericum perforatum) on human cytochrome P450 activity. Clin Pharmacol Ther 70(4):317–326
  Article PubMed CAS Google Scholar
• Johne A, Brockmoller J, Bauer S, Maurer A, Langheinrich M, Roots I (1999) Pharmacokinetic interaction of digoxin with an herbal extract from St John’s wort (Hypericum perforatum). Clin Pharmacol Ther 66(4):338–345
  Article PubMed CAS Google Scholar
• Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, Falloon J (2000) Indinavir concentrations and St John’s wort. Lancet 355(9203):547–548
  Article PubMed CAS Google Scholar
• Ruschitzka F, Meier PJ, Turina M, Luscher TF, Noll G (2000) Acute heart transplant rejection due to Saint John’s wort [letter] [see comments]. Lancet 355(9203):548–549
  Article PubMed CAS Google Scholar
• Obach RS (2000) Inhibition of human cytochrome P450 enzymes by constituents of St. John’s Wort, an herbal preparation used in the treatment of depression. J Pharmacol Exp Ther 294(1):88–95
  PubMed CAS Google Scholar
• Hennessy M, Kelleher D, Spiers JP, Barry M, Kavanagh P, Back D, Mulcahy F, Feely J (2002) St John’s Wort increases expression of P-glycoprotein: Implications for drug interactions. Br J Clin Pharmacol 53:75–82
  Article PubMed CAS Google Scholar
• Markowitz JS, DeVane CL, Boulton DW, Carson SW, Nahas Z, Risch SC (2000) Effect of St. John’s wort (Hypericum perforatum) on cytochrome P-450 2D6 and 3A4 activity in healthy volunteers. Life Sci 66(9):L133–L139
  Article Google Scholar
• Rengelshausen J, Banfield M, Riedel KD, Burhenne J, Weiss J, Thomsen T, Walter-Sack I, Haefeli WE, Mikus G (2005) Opposite effects of short-term and long-term St John’s wort intake on voriconazole pharmacokinetics. Clin Pharmacol Ther 78(1):25–33
  Article PubMed CAS Google Scholar
• Izzo AA, Ernst E (2001) Interactions between herbal medicines and prescribed drugs: a systematic review. Drugs 61(15):2163–2175
  Article PubMed CAS Google Scholar
• Mills E, Montori VM, Wu P, Gallicano K, Clarke M, Guyatt G (2004) Interaction of St John’s wort with conventional drugs: systematic review of clinical trials. BMJ 329(7456):27–30
  Article PubMed Google Scholar
• Ernst E (1999) Second thoughts about safety of St John’s wort. Lancet 354(9195):2014–2016
  Article PubMed CAS Google Scholar
• Medical Products Agency, Sweden. St John’s Wort may influence other medications. In; 2002
• Schwarz UI, Buschel B, Kirch W (2003) Unwanted pregnancy on self medication with St John’s Wort despite hormonal contraception. Br J Clin Pharmacol 55:112–113
  Article PubMed Google Scholar
• Hall SD, Wang Z, Huang SM, Hamman MA, Vasavada N, Adigun AQ, Hilligoss JK, Miller M, Gorski JC (2003) The interaction between St John’s wort and an oral contraceptive. Clin Pharmacol Ther 74(6):525–535
  Article PubMed CAS Google Scholar
• Murphy PA, Kern SE, Stanczyk FZ, Westhoff CL (2005) Interaction of St. John’s Wort with oral contraceptives: effects on the pharmacokinetics of norethindrone and ethinyl estradiol, ovarian activity and breakthrough bleeding. Contraception 71(6):402–408
  Article PubMed CAS Google Scholar
• Pfrunder A, Schiesser M, Gerber S, Haschke M, Bitzer J, Drewe J (2003) Interaction of St John’s wort with low-dose oral contraceptive therapy: a randomized controlled trial. Br J Clin Pharmacol 56(6):683–690
  Article PubMed CAS Google Scholar
• Guengerich FP (1990) Metabolism of 17 alpha-ethinyl estradiol in humans. Life Sci 47:1981–1988
  Article PubMed CAS Google Scholar
• Shader RI, Oesterheld JR (2000) Contraceptive effectiveness: cytochromes and induction. J Clin Psychopharmacol 20:119–121
  Article PubMed CAS Google Scholar
• Shane-McWhorter L, Cerveny JD, MacFarlane LL, Osborn C (1998) Enhanced metabolism of levonorgestrel during phenobarbital treatment and resultant pregnancy. Pharmacotherapy 18(6):1360–1364
  PubMed CAS Google Scholar
• Haukkamaa M (1986) Contraception by Norplant subdermal capsules is not reliable in epileptic patients on anticonvulsant treatment. Contraception 33(6):559–565
  Article PubMed CAS Google Scholar
• Odlind V, Olsson SE (1986) Enhanced metabolism of levonorgestrel during phenytoin treatment in a woman with Norplant implants. Contraception 33(3):257–261
  Article PubMed CAS Google Scholar
• Gentile DM, Verhoeven CH, Shimada T, Back DJ (1998) The role of CYP2C in the in vitro bioactivation of the contraceptive steroid desogestrel. J Pharmacol Exp Ther 287(3):975–982
  PubMed CAS Google Scholar
• Burstein AH, Horton RL, Dunn T, Alfaro RM, Piscitelli SC, Theodore W (2000) Lack of effect of St John’s Wort on carbamazepine pharmacokinetics in healthy volunteers. Clin Pharmacol Ther 68(6):605–612
  Article PubMed CAS Google Scholar
• Gu L, Gonzalez FJ, Kalow W, Tang BK (1992) Biotransformation of caffeine, paraxanthine, theobromine and theophylline by cDNA-expressed human CYP1A2 and CYP2E1. Pharmacogenetics 2(2):73–77
  Article PubMed CAS Google Scholar
• Bilia AR, Gallori S, Vincieri FF (2002) St. John’s wort and depression: efficacy, safety and tolerability-an update. Life Sci 70(26):3077–3096
  Article PubMed CAS Google Scholar
• Ernst E (1999) Herbal medications for common ailments in the elderly. Drugs Aging 15(6):423–428
  Article PubMed CAS Google Scholar
• Henderson L, Yue QY, Bergquist C, Gerden B, Arlett P (2002) St John’s wort (Hypericum perforatum): drug interactions and clinical outcomes. Br J Clin Pharmacol 54(4):349–356
  Article PubMed CAS Google Scholar
• Nebel A, Schneider BJ, Baker RK, Kroll DJ (1998) Potential metabolic interaction between St John’s Wort and theophylline. Ann Pharmacother 33:202
  Google Scholar
• Morimoto T, Kotegawa T, Tsutsumi K, Ohtani Y, Imai H, Nakano S (2004) Effect of St. John’s wort on the pharmacokinetics of theophylline in healthy volunteers. J Clin Pharmacol 44(1):95–101
  Article PubMed CAS Google Scholar
• Komoroski BJ, Zhang S, Cai H, Hutzler JM, Frye R, Tracy TS, Strom SC, Lehmann T, Ang CY, Cui YY, Venkataramanan R (2004) Induction and inhibition of cytochromes P450 by the St. John’s wort constituent hyperforin in human hepatocyte cultures. Drug Metab Dispos 32(5):512–518
  Article PubMed CAS Google Scholar
• Keech A, Collins R, MacMahon S, Armitage J, Lawson A, Wallendszus K, Fatemian M, Kearney E, Lyon V, Mindell J, et al (1994) Three-year follow-up of the Oxford Cholesterol Study: assessment of the efficacy and safety of simvastatin in preparation for a large mortality study. Eur Heart J 15(2):255–269
  PubMed CAS Google Scholar
• Christians U, Jacobsen W, Floren LC (1998) Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar? Pharmacol Ther 80(1):1–34
  Article PubMed CAS Google Scholar
• Vickers S, Duncan CA, Vyas KP, Kari PH, Arison B, Prakash SR, Ramjit HG, Pitzenberger SM, Stokker G, Duggan DE (1990) In vitro and in vivo biotransformation of simvastatin, an inhibitor of HMG CoA reductase. Drug Metab Dispos 18(4):476–483
  PubMed CAS Google Scholar
• Sugimoto K, Ohmori M, Tsuruoka S, Nishiki K, Kawaguchi A, Harada K, Arakawa M, Sakamoto K, Masada M, Miyamori I, Fujimura A (2001) Different effects of St John’s wort on the pharmacokinetics of simvastatin and pravastatin. Clin Pharmacol Ther 70(6):518–524
  Article PubMed CAS Google Scholar
• Moore LB, Goodwin B, Jones SA, Wisely GB, Serabjit-Singh CJ, Willson TM, Collins JL, Kliewer SA (2000) St. John’s wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci USA 97(13):7500–7502
  Article PubMed CAS Google Scholar
• Cantoni L, Rozio M, Mangolini A, Hauri L, Caccia S (2003) Hyperforin contributes to the hepatic CYP3A-inducing effect of Hypericum perforatum extract in the mouse. Toxicol Sci 75(1):25–30
  Article PubMed CAS Google Scholar
• Butterweck V, Christoffel V, Nahrstedt A, Petereit F, Spengler B, Winterhoff H (2003) Step by step removal of hyperforin and hypericin: activity profile of different Hypericum preparations in behavioral models. Life Sci 73(5):627–639
  PubMed CAS Google Scholar
• Laakmann G, Schule C, Baghai T, Kieser M (1998) St. John’s wort in mild to moderate depression: the relevance of hyperforin for the clinical efficacy. Pharmacopsychiatry 31 Suppl 1:54–59
  PubMed CAS Google Scholar
• Schrader E, Meier B, Brattstrom A (1998) Hypericum treatment of mild-moderate depression in a placebo-controlled study. A prospective, double-blind, randomized, placebo-controlled, multicentre study. Human Psychopharmacol 13:163–169
  Article Google Scholar
• Mueller SC, Majcher-Peszynska J, Klammt S, Uehleke B, Miekisch B, Kundt G, Drewelow B (2005) Induction of CYP3A by St. Johns Wort (SJW) depends on hyperforin (HYF) dose ABSTRACT. Clin Pharmacol Ther 77(2):P36
  Article Google Scholar